Please login to the form below

Not currently logged in
Email:
Password:

Trial success for Forest's depression drug

Forest Laboratories has said preliminary results from a phase III trial of major depressive disorder treatment, levomilnacipran, indicate the drug achieved a statistically significant improvement in patients compared to placebo

Forest Laboratories has said preliminary results from a phase III trial of major depressive disorder treatment, levomilnacipran, indicate the drug achieved a statistically significant improvement in patients compared to placebo.

The drug's efficacy was based on the primary endpoint of a patient's change from baseline to end of week 8 in the Montgomery-Asberg Depression Rating Scale-Clinician Rated (MADRS-CR) total score.

Levomilnacipran is co-developed by Forest and France-based laboratory Pierre Fabre Medicament.

"These positive phase III results are very encouraging and support the continued research of levomilnacipran in adult patients with major depressive disorder," said Dr Marco Taglietti, senior vice president, R&D, and president, Forest Research Institute.

Further analysis of the study data is ongoing, with two additional placebo-controlled phase III studies expected at the end of 2011 and in spring 2012, respectively.

18th July 2011

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Rainmaker Healthcare Communications

Rainmaker is an independent, award-winning communications agency with offices in London and Atlanta. Our experience across pharmaceuticals, generics, OTC, medical...

Latest intelligence

women
Advancing women in healthcare
Fostering the next generation of leaders...
The Challenges Of UX In Healthcare: Technology To Change Lives
Blue Latitude Health Director and Head of Customer Experience Elisa Del Galdo explores the latest digital healthcare trends and reveals the innovations changing the sector today....
It’s all about patient outcomes… right?
Lessons from history: a design thinking perspective...

Infographics